Tyme Technologies Quick Ratio (TYME) starting from the first quarter 2022 to first quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Tyme Technologies Inc.  (NASDAQ: TYME)

Tyme Technologies's Quick Ratio

TYME's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Tyme Technologies's Cash & cash equivalent grew by 3.7 % in the Q1 2022 sequentially, while Current Liabilities decreased, this led to improvement in Tyme Technologies's Quick Ratio to 13.72, above Tyme Technologies Inc. average Quick Ratio.

Within Major Pharmaceutical Preparations industry 120 other companies have achieved higher Quick Ratio than Tyme Technologies in first quarter 2022. While Quick Ratio total ranking has improved so far during the Q1 2022 to 387, from total ranking in the fourth quarter 2022 at 529.

Explain Quick Ratio?
How much Cash & cash equivalents TYME´s has?
What are TYME´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TYME Quick Ratio (Jun 30 2022)
Q1		 (Mar 31 2022)
Q4		 (Dec 31 2021)
Q3		 (Sep 30 2021)
Q2		 (Jun 30 2021)
Q1
Y / Y Current Liabilities Change 21.37 % 30.86 % 18.23 % -16.97 % -18.89 %
Y / Y Cash & cash equivalent Change 6.17 % -30.85 % 456.5 % 289.25 % 240.77 %
Quick Ratio MRQ 13.72 10.07 13.77 15.82 15.68
TYME's Total Ranking # 387 # 529 # 224 # 398 # 332
Seq. Current Liabilities Change -23.89 % 35.45 % 14.25 % 3.04 % -17.94 %
Seq. Cash & cash equivalent Change 3.7 % -0.94 % -0.6 % 3.98 % -32.45 %



Quick Ratio first quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 184
Overall Market # 387


Quick Ratio Statistics
High Average Low
19.05 5.72 1.15
(Mar 31 2021)   (Dec 31 2016)




Financial Statements
Tyme Technologies's Current Liabilities $ 6 Millions Visit TYME's Balance sheet
Tyme Technologies's Cash & cash equivalent $ 77 Millions Visit TYME's Balance sheet
Source of TYME's Sales Visit TYME's Sales by Geography


Cumulative Tyme Technologies's Quick Ratio

TYME's Quick Ratio for the trailling 12 Months

TYME Quick Ratio

 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months		 (Dec 31 2021)
12 Months		 (Sep 30 2021)
12 Months		 (Jun 30 2021)
12 Months
Y / Y Current Liabilities TTM Growth 12.58 % 2.43 % -5.32 % -11.88 % -2.2 %
Y / Y Cash & cash equivalent TTM Growth 41.78 % 83.99 % 308.8 % 241.21 % 184.85 %
Quick Ratio TTM 13 13.38 16.13 13.69 10.32
Total Ranking TTM # 4572 # 4554 # 4397 # 206 # 4731
Seq. Current Liabilities TTM Growth 4.45 % 8.5 % 4.28 % -4.73 % -4.97 %
Seq. Cash & cash equivalent TTM Growth 1.51 % -10.03 % 22.88 % 26.34 % 31.73 %

Quick ratio ranking by company, industry and sector >> Back to TYME Financial Strength Comparisons >> Go to Compare TYME Quick Ratio to its Competitors

On the trailing twelve months basis Due to decline in Current Liabilities in the Q1 2022 to $5.62 millions, cumulative Quick Ratio decreased to 13 above the TYME average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 567 other companies have achieved higher Quick Ratio than Tyme Technologies. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2022 from 4554 to 4572.

Explain Quick Ratio?
How much Cash & cash equivalents TYME´s has?
What are TYME´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 568
Healthcare Sector # 1118
Within the Market # 4572


trailing twelve months Quick Ratio Statistics
High Average Low
16.13 6.38 2.35
(Dec 31 2021)   (Jun 30 2017)




Companies with similar Quick Ratio in the quarter ending Jun 30 2022, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2022 MRQ Cash & cash equivalentJun 30 2022 MRQ Current Liabilities
Enliven Therapeutics Inc   37.06 $ 122.363  Millions$ 3.302  Millions
Immuneering Corporation  36.45 $ 128.101  Millions$ 3.514  Millions
Nanoviricides inc   34.08 $ 14.070  Millions$ 0.413  Millions
Atossa Therapeutics Inc   33.13 $ 125.647  Millions$ 3.792  Millions
Nuvation Bio Inc   33.08 $ 703.797  Millions$ 21.274  Millions
Silo Pharma Inc  32.49 $ 8.734  Millions$ 0.269  Millions
Nkarta Inc   31.32 $ 412.951  Millions$ 13.184  Millions
Infinity Pharmaceuticals Inc   31.21 $ 56.575  Millions$ 1.813  Millions
Day One Biopharmaceuticals Inc   30.85 $ 394.864  Millions$ 12.799  Millions
Briacell Therapeutics Corp   30.42 $ 41.042  Millions$ 1.349  Millions
Merrimack Pharmaceuticals Inc  30.28 $ 13.355  Millions$ 0.441  Millions
Moonlake Immunotherapeutics  30.24 $ 92.708  Millions$ 3.066  Millions
Spruce Biosciences Inc   29.63 $ 93.295  Millions$ 3.149  Millions
Eqrx Inc   29.59 $ 1,557.347  Millions$ 52.636  Millions
Kura Oncology Inc   28.89 $ 450.258  Millions$ 15.583  Millions
Anebulo Pharmaceuticals Inc   28.39 $ 14.548  Millions$ 0.513  Millions
Hcw Biologics Inc   28.32 $ 32.414  Millions$ 1.144  Millions
Xbiotech Inc   27.42 $ 225.793  Millions$ 8.235  Millions
An2 Therapeutics Inc   27.33 $ 113.389  Millions$ 4.149  Millions
Janux Therapeutics Inc   27.27 $ 354.296  Millions$ 12.994  Millions
Atea Pharmaceuticals Inc   27.26 $ 684.480  Millions$ 25.107  Millions
Morphic Holding inc   26.10 $ 397.560  Millions$ 15.232  Millions
Nuvalent Inc   25.60 $ 256.964  Millions$ 10.036  Millions
Forte Biosciences Inc   25.48 $ 38.548  Millions$ 1.513  Millions
Diamedica Therapeutics Inc   25.40 $ 38.551  Millions$ 1.518  Millions
Pmv Pharmaceuticals Inc   24.37 $ 277.434  Millions$ 11.383  Millions
Anaptysbio Inc   24.16 $ 442.151  Millions$ 18.301  Millions
Disc Medicine Inc   23.98 $ 108.659  Millions$ 4.531  Millions
Dice Therapeutics Inc   23.39 $ 282.221  Millions$ 12.066  Millions
Terns Pharmaceuticals Inc   23.13 $ 139.810  Millions$ 6.044  Millions

Date modified: 2026-09-08T15:10:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.